Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
| MER Indicator |
MER description |
Target Fiscal Year |
Target |
| HTS_TST |
By Key Population: MSM, Negative |
2018 |
358 |
| HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2018 |
390 |
| HTS_TST |
Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative |
2018 |
358 |
| HTS_TST |
Sum of Test Result disaggregates |
2018 |
32 |
| HTS_TST_POS |
By Key Population: MSM, Positive |
2018 |
32 |
| HTS_TST_POS |
By Test Result: Positive |
2018 |
32 |
| HTS_TST_POS |
Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive |
2018 |
32 |
| TX_CURR |
Aggregated Age/Sex: 15+ Female |
2018 |
1,479 |
| TX_CURR |
Aggregated Age/Sex: 15+ Male |
2018 |
2,219 |
| TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2018 |
3,698 |
| TX_CURR |
Sum of Aggregated Age/Sex 15+ |
2018 |
3,698 |
| TX_CURR |
Sum of Aggregated Age/Sex disaggregates |
2018 |
3,698 |
| TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Female |
2018 |
259 |
| TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Male |
2018 |
389 |
| TX_NEW |
MSM |
2018 |
194 |
| TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2018 |
648 |
| TX_NEW |
Sum of Aggregated Age/Sex disaggregates |
2018 |
648 |
| TX_PVLS |
Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months |
2018 |
2,662 |
| TX_PVLS |
Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months |
2018 |
2,397 |
| TX_PVLS |
Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine |
2018 |
957 |
| TX_PVLS |
Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine |
2018 |
1,439 |
| TX_PVLS |
Numerator: Indication: Routine |
2018 |
2,397 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine |
2018 |
1,065 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine |
2018 |
1,597 |
| TX_PVLS_den |
Denominator: Indication: Routine |
2018 |
2,662 |
| TX_RET |
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2018 |
113 |
| TX_RET |
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2018 |
168 |
| TX_RET |
Number of adults and children who are still alive and on treatment at 12 months after initiating ART |
2018 |
518 |
| TX_RET |
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up |
2018 |
648 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2018 |
259 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2018 |
389 |
